Provided by Tiger Trade Technology Pte. Ltd.

XILIO THERAPEUTICS, INC.

9.19
-0.0400-0.43%
Post-market: 9.190.00000.00%19:30 EDT
Volume:2K
Turnover:21.12K
Market Cap:60.47M
PE:-2.77
High:9.32
Open:9.32
Low:9.17
Close:9.23
52wk High:12.74
52wk Low:6.47
Shares:6.58M
Float Shares:3.40M
Volume Ratio:0.15
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3174
EPS(LYR):-15.2374
ROE:-55.03%
ROA:-13.61%
PB:0.84
PE(LYR):-0.60

Loading ...

Xilio Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Xilio Therapeutics Inc Expected to Post a Loss of 92 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Xilio Therapeutics - Plans to Report Initial Phase 1 Data in Patients with Metastatic Nsclc in H2 2027

THOMSON REUTERS
·
Aug 12

Xilio Therapeutics - Expects Cash Runway into Q1 2028

THOMSON REUTERS
·
Aug 12

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

THOMSON REUTERS
·
Aug 12

Xilio Therapeutics Grants Inducement Stock Options for 107,060 Shares at $9.22 Each

Reuters
·
Jul 07

Xilio Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 07

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

THOMSON REUTERS
·
Jun 29

Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes

TIPRANKS
·
Jun 13

Xilio Therapeutics shareholders approved amended and restated 2021 stock incentive plan update

Reuters
·
Jun 13

Xilio Therapeutics files $250M mixed securities shelf

TIPRANKS
·
May 13

Xilio Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 12

Xilio Therapeutics Inc - May Offer up to $17.22 Mln Common Stock Under Sales Agreement With Leerink Partners - SEC Filing

THOMSON REUTERS
·
May 12

Press Release: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Dow Jones
·
May 12

Xilio Therapeutics grants new hire stock options for 1,982 shares at $8.32 each

Reuters
·
May 08

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 08

Xilio Therapeutics Inc expected to post a loss of 66 cents a share - Earnings Preview

Reuters
·
May 06

Xilio announces new preclinical data for XTX601 at AACR

TIPRANKS
·
Apr 18

Xilio plans IND filing in 2027 for masked CLDN18.2 T-cell engager XTX601

Reuters
·
Apr 18

Xilio Therapeutics Announces Board Changes and Committee Leadership

TIPRANKS
·
Apr 16